Fiche du document
30 août 2023
- doi: 10.53738/REVMED.2023.19.839.1554
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.839.1554
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37650593
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B38DE2D08B8C8
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2025-03-01 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Campylobacter pyloriCiter ce document
J. Voirol-Perrin et al., « Dyspepsie fonctionnelle : update 2023 [Functional dyspepsia : update 2023] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.839.1554
Métriques
Partage / Export
Résumé
Functional dyspepsia is defined by epigastric pain/burning, postprandial fullness and/or early satiety that have been present for at least six months before diagnosis, including three consecutive months, without evidence of an organic cause likely to explain these symptoms. The pathogenesis is complex and incompletely understood. The initial assessment includes a thorough history, physical examination, blood work, celiac disease serology and ruling out Helicobacter pylori infection. Most patients will undergo upper gastrointestinal endoscopy and abdominal ultrasound to exclude organic differential diagnoses. The therapy is multi-facetted and includes, among others, proton pump inhibitors, Helicobacter pylori eradication, herbal agents, and neuromodulators.